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Chronic obstructive pulmonary disease appears to oc-
cur slowly and progressively over many years, with
both genetic factors and environmental modifiers
contributing to its pathogenesis. Although the c-Jun/
activator protein 1 transcriptional factor regulates cell
proliferation, apoptosis, and inflammatory responses,
its role in lung pathogenesis is largely unknown. In this
study, we report decreased expression levels of c-Jun
mRNA and protein in the lung tissues of patients with
advanced chronic obstructive pulmonary disease, and
the genetic deletion of c-Jun specifically in alveolar ep-
ithelial cells causes progressive emphysema with lung
inflammation and alveolar air space enlargement, which
are cardinal features of emphysema. Although mice
lacking c-Jun specifically in lung alveolar epithelial
cells appear normal at the age of 6 weeks, when
exposed to long-term cigarette smoke, c-Jun–mu-
tant mice display more lung inflammation with
perivascular and peribronchiolar infiltrates com-
pared with controls. These results demonstrate that
the c-Jun/activator protein 1 pathway is critical for
maintaining lung alveolar cell homeostasis and that
loss of its expression can contribute to lung inflam-
mation and progressive emphysema. (Am J Pathol
2012, 180:562–574; DOI: 10.1016/j.ajpath.2011.10.029)
Chronic obstructive pulmonary disease (COPD) is pro-
jected to be the third-leading cause of death worldwide
by 2020.1,2 COPD is a chronic lung disease character-
562ized by severely impaired normal lung function. The de-
velopment of COPD appears to occur slowly and pro-
gressively over many years; it is generally diagnosed in
middle-aged or older individuals.2 Exposure to cigarette
smoke is a major risk factor for the development of
COPD.3 Only a subset of cigarette smokers develop
COPD; other factors, such as air pollution and infections,
also contribute to its pathogenesis, suggesting that both
genetic factors and environmental modifiers contribute to
the development of COPD.4 Although the mechanisms
underlying the development and progression of this dis-
ease remain enigmatic, a histopathological examination
of the lungs of patients with severe COPD has revealed a
severe loss of lung tissue, especially of the alveolar type
II cells, and persistent lung inflammation.5 Data obtained
from molecular and cellular analyses of lung tissue sam-
ples from patients with COPD and from experimental
mouse models of emphysema have suggested critical
roles for deregulated cell proliferation, antioxidant-oxi-
dant imbalance, apoptosis, and degradation of the extra-
cellular matrix in COPD.6
The activator protein 1 (AP-1), composed of the c-Jun
(c-Jun, Jun-B, and Jun-D) and Fos (Fos, Fos-B, Fra-1,
and Fra-2) families of DNA-binding proteins, binds to the
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element (TRE, TGAC/GTCA) and regulates the expres-
sion of genes involved in various biological processes,
including cell proliferation, differentiation, cell death, in-
flammation, and cellular defense.7 Various cellular pro-
cesses controlled by the AP-1 transcriptional factor have
been deregulated in lung tissue/cell types obtained from
patients with COPD.5 Although the members of the AP-1
family of proteins are activated in response to various
insults in lung epithelial cells,8 whether the activation of
AP-1 proteins is critical to confer protection on the host or
to enhance the host’s susceptibility to the development
and progression of lung diseases is still largely undefined
in vivo. Thus, in the present study, we have examined the
role of c-Jun/AP-1 transcription factors in COPD. First, we
determined the expression levels of this transcription fac-
tor in COPD clinical samples and found the loss of c-Jun
expression in the lung tissues obtained from patients with
severe COPD [Global Initiative for Obstructive Lung Dis-
ease (GOLD) stage IV] when compared with control in-
dividuals without COPD. Because conventional deletion
of c-Jun results in embryonic lethality,9 we used a mouse
model in which c-Jun was specifically deleted in type II
alveolar epithelial cells. We then examined the effects of
c-Jun deficiency on both lung development and cigarette
smoke–induced lung inflammation and tissue destruction
in these mice. Herein, we report, for the first time to our
knowledge, that the c-Jun deficiency in alveolar type II
epithelial cells results in progressive emphysema and
perpetuates cigarette smoke–induced lung inflammation
in vivo.
Materials and Methods
Human Lung Tissue Samples
Lung tissue samples used in this study were obtained
from the Lung Tissue Research Consortium funded by
the National Heart, Lung, and Blood Institute. One tissue
sample was obtained from each subject (ie, n represents
the number subjects in this study). Patients’ lung function
data were obtained from established patient registries.
The subjects were classified as per severity of COPD,
Table 1. Clinical and Demographic Characteristics of the Study P
Characteristics Non-COPD
Age, mean  SD (years) 63.1  11.5
Sex
Male 11
Female 10
Smoking status
Current 1
Ever 14
Never 6
Not known 0
Pack-years, mean  SD 43.8 40.4
Pulmonary function parameters
FEV1, mean  SD (%) 91.5  8.2
FCV, mean  SD (%) 95.1  9.2
GOLD stage (0/I/II/III/IV) 14/7/0/0/0FCV, forced vital capacity.according to the guidelines of the GOLD. The non-COPD
population (21 samples with 15 former smokers, one cur-
rent smoker, and five never smokers) had normal lung
function performance and no evidence of COPD (Table
1). Groups for COPD lungs included GOLD-II, GOLD-III,
and GOLD-IV on the basis of lung function test results.
The clinical and demographic characteristics of these
patients are presented in Table 1.
Mice
Mice carrying the floxed c-Jun allele (hereafter referred to
as c-Junf/f) were generated on a C57BL/6129SVJ back-
ground, as described elsewhere.10 Mice expressing Cre
recombinase under the control of surfactant protein C
(SPC) promoter on a C57BL/6 background were obtained
from Dr. Brigid Hogan, Duke University (Durham, NC).11
Wild-type mice with a C57BL/6129SVJ background
were used as additional controls in selective experi-
ments. To generate the mice with c-Jun deletion in alve-
olar type II epithelial cells, c-Junf/fmice were crossed with
SPC-Cre mice (see Supplemental Figure S1A at http://
ajp.amjpathol.org). The resulting c-Junf/wt-SPC-Cre mice
were backcrossed to the parental c-Junf/f mice to obtain
c-Junf/f- SPC-Cremice (hereafter referred to as c-Junae).
All animal protocols were performed in accordance with
guidelines approved by the animal care and use com-
mittee at the Johns Hopkins University (Baltimore, MD).
PCR Genotyping and Determination of c-Jun
Deletion in Alveolar Epithelial Cells
We used the Jun1 [5=-CTCATACCAGTTCGCACAG-
GCGGC-3= (forward)] and Jun2 [5=-CCGCTAGCACT-
CACGTTGGTAGGC-3= (reverse)] primers for the detec-
tion of floxed alleles. For the detection of SPC-Cre, the
SPC [5=-GACACATATAAGACCCTGGTCA-3= (forward)]
and Cre [5=-ACGAACCTGGTCGAAATCAGTGCG-3= (re-
verse)] primers were used as outlined (see Supplemental
Figure S1B at http://ajp.amjpathol.org). Alveolar type II
epithelial cells were isolated and cultured, as previously
described.12 For the detection of c-Jun deletion in lung
epithelium, the genomic DNA from type II epithelial cells
ion
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GTCACTGAGCT-3=, reverse) primers (see Supplemental
Figure S1B at http://ajp.amjpathol.org).
Cigarette Smoke Exposure
Mice (aged 8 weeks) were divided into two groups: con-
trol and cigarette smoke exposure groups. Control
groups were housed in a filtered air environment. Exper-
imental groups were subjected to cigarette smoke expo-
sure for 5 hours/day, 5 days/week for 6 months using a
whole-body smoke exposure system (model TE-10; Tea-
gue Enterprises, Woodland, CA) using 2R4F reference
cigarettes with 2.45 mg of nicotine per cigarette (To-
bacco Research Institute, University of Kentucky, Lexing-
ton, KY), as described elsewhere.13 Each smoldering
cigarette was puffed for 2 seconds, once every minute,
for a total of 8 puffs, at a flow rate of 1.05 L/minute, to
provide a standard puff of 35 cm3. The smoke machine
was adjusted to produce a mixture of sidestream smoke
(89%) and mainstream smoke (11%) by burning five cig-
arettes at one time. The chamber atmosphere was mon-
itored for total suspended particles and carbon monox-
ide, with concentrations of 90 mg/m3 and 350 ppm,
respectively.
Lung Morphological Measurements
Lung morphometric measurements were performed, as
previously described.14,15 Mice were anesthetized with
sodium pentobarbital, and lungs were inflated with
warmed (50°C to 55°C) 0.8% low-melt agarose in 1.5%
paraformaldehyde at 25 to 30 cm H2O. The inflation pres-
sure was measured continuously until the agarose
started to gel (approximately 1 minute). The whole animal
was placed in a refrigerator at 4°C for 30 minutes. The
cooled agarose-filled lungs were excised and placed in
1.5% paraformaldehyde for 24 hours at 4°C. Lung tissues
were washed in distilled water and placed in 70% ethyl
alcohol. Before histological sectioning, the left lung was
dissected, and the inferior and superior 3 mm along the
long axis of the lung was removed. The remaining tissue
was cut into three sections (2 to 3 mm thick) and embed-
ded in paraffin. Sections (5 m thick) were cut and
stained with H&E. The slides were coded, and represen-
tative images (15 per lung section) were acquired with
Nikon Digital Camera DXM1200 (Nikon, Tokyo, Japan) at
100 magnification. The mean chord length (MCL) was
measured using ImageJ software (NIH, Bethesda, MD)
and computer-assisted morphometry with Image Pro Plus
software, with sampling grid lines 17 m apart, ensuring
one to two chords per alveolus. Arteries, veins, or bron-
chioles were avoided in morphometric measurements.
TUNEL Assay
DNA damage was assessed using the In Situ Cell
Death Detection Kit (Roche Applied Science, Indianap-
olis, IN), per manufacturer’s instructions. Briefly, the
lung tissue sections were deparaffinized, washed with
PBS, blocked with 3% H2O2 in methanol, permeabil-ized, and then incubated with 50 L of TUNEL mixture
for 1 hour at 37°C. The sections were analyzed under a
fluorescent microscope, and the images were cap-
tured. The number of TUNEL-positive cells in tissue
sections (10 fields per lung section) was counted and
expressed as mean  SEM.
Assessment of Lung Inflammation
Mice were anesthetized, tracheas were cannulated, and
lungs were lavaged twice with 1 mL of cold PBS. Cells
from the bronchoalveolar lavage (BAL) fluid were centri-
fuged, and total inflammatory cells were counted using a
hemocytometer. Differential cell counts were determined
by staining with the Diff-Quick Stain Set (Dade-Behring,
Newark, DE). For each sample, 300 cells (macrophages,
neutrophils, and lymphocytes) were counted based on
standard cytological criteria.
Cytokine Analysis
The BAL fluid samples from mice were analyzed by the
multiplex suspension array system using Luminex beads
(Bio-Rad Laboratories, Hercules, CA), which included the
following cytokines: IL-1, IL-1, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, eotaxin,
granulocyte cell–stimulating factor, granulocyte macro-
phage colony-stimulating factor, interferon-, monocyte
chemoattractant protein 1, macrophage inflammatory
protein (MIP) 1, MIP-1, and tumor necrosis factor 
(TNF-). The BAL fluid samples of different age groups
were thawed, diluted 1:1 with diluent, run according to
the manufacturer’s protocol, and measured as pg/mL of
BAL fluid (n  3 to 5).
Real-Time RT-PCR
Total RNA was isolated from the lungs of c-Junf/f and
c-Junae mice and the lung tissues of human patients
without COPD or with moderate, severe, and very severe
COPD using the RNeasy kit (Qiagen, Germantown, MD)
and reverse transcribed with the superscript first-strand
cDNA synthesis system (Invitrogen, Carlsbad, CA). Real-
time RT-PCR was performed using TaqMan gene expres-
sion assays specific for mouse Gclc, Nqo1, and Hmox1
and human c-JUN. For the detection of surfactant protein
A (SPA), SPC, and SPD expression, we used SYBR
Green 1 dye reagent (Applied Biosystems, Carlsbad, CA)
and gene-specific primer sets. The following primers
were used: SPA, 5=-CAGTGTGATTGGGAGAAACC-3=
(forward) and 5=-TGTCTCCATGTTCTCCAGGT-3= (re-
verse); SPC, 5=-CAAAGAGGTCCTGATGGAGA-3= (for-
ward) and 5=-TCATACACAACGATGCCAGT-3= (reverse);
SPD, 5=-GGCTGCTTTCC TGAGTATGA-3= (forward) and
5=-GGCAACATACAGGTCTGAGC-3= (reverse); and
-actin, 5=-CTACAATGAGCTGCGTGTGGC-3= (forward)
and 5=-CGAACAATTTCCCTCTCAGC-3= (reverse). The
absolute expression values for each gene were normal-
ized to that of actin, and values from 1.5-month-old
c-Junae mice samples were set as one unit. Fold
changes for c-JUN expression in COPD samples were
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Western Blot Analysis
Non-COPD and severe and very severe COPD lung
tissues were homogenized, and protein concentrations
were estimated using the bicinchoninic acid reagent
(Thermo Scientific, Rockford, IL). Equal amounts of
protein were separated and immunoblotted with anti-
c-JUN antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA). The blots were developed with the electro-
chemiluminescence Western blot detection system
(Thermo Scientific). Bands were quantified using -ac-
tin as the reference.
Immunohistochemistry
Immunohistochemical (IHC) staining on human COPD
lung tissue sections and on lung tissue sections of c-Junf/f
and c-Junae mice exposed to cigarette smoke was per-
formed as previously reported.16 Briefly, tissue slides were
deparaffinized and rehydrated. After antigen recovery with
DakoCytomation Target Retrieval Solution, pH 9 (Dako, Car-
pentaria, CA), for 20 minutes in a microwave oven, nonspe-
cific binding was blocked with 3% bovine serum albumin
solution. IHC staining was performedwith anti-c-JUN (Santa
Cruz Biotechnology), anti-B220 (BD Biosciences, Franklin
Lakes, NJ), or anti-CD3 (Dako, Carpentaria, CA) antibodies.
Staining was visualized with the Dako Universal LSAB
horseradish peroxidase kit (Dako), following manufacturer’s
recommendations.
Statistical Analysis
All data involving COPD samples (non-COPD, moderate
COPD, severe COPD, and very severe COPD; n  88 for
c-JUN mRNA analyses, and n  36 for c-JUN protein
analyses) were described by median, interquartile range,
and scatterplots. We compared the relative expression
levels of c-JUN mRNA and protein in lung tissue samples
from individuals with moderate, severe, and very severe
COPD with non-COPD control samples; our main com-
parison used linear regression models without any ad-
justment and with further adjustment for sex, age, and
cigarette pack-years. We also used Bonferroni correction
for multiple comparisons.
All animal data were expressed as the mean SEM (n
8 for each condition). One-way analysis of variance, fol-
lowed by Newman-Keuls post hoc analysis, was performed
for multiple comparisons. P  0.05 was considered statis-
tically significant. For comparing the interaction between
age and genotype, two-way analysis of variance with a
Bonferroni correction was used. Bonferroni-corrected P 
0.05 was used to identify statistical significance.Results
Deregulation of c-JUN Expression in COPD
Lung Tissues
To determine whether c-JUN expression is dysregulated
with the progression of emphysema in humans, we mea-
sured the expression levels of c-JUN mRNA and protein
in non-COPD [forced expiratory volume in 1 second
(FEV1) 80%, GOLD-0/GOLD-1], moderate COPD (FEV1
50% to 80%, GOLD II), severe COPD (FEV1 30% to
50%, GOLD-III), and very severe COPD (FEV1 30%,
GOLD-IV) lung tissue samples. The clinical and demo-
graphic characteristics of the patients with COPD are
given in Table 1. Compared with non-COPD lung tissue
samples, c-JUN mRNA levels were significantly de-
creased in lungs with very severe COPD (0.45-fold lower,
P  0.008) but not in lungs with moderate COPD (0.88-
fold lower, P  0.58) and severe COPD (0.66-fold lower,
P 0.19; Figure 1A). The decreased c-JUNmRNA levels
comparing very severe COPD with non-COPD lung tissue
were similar after adjustment for age, sex, and pack-
years (P  0.009). By using Bonferroni corrections for
multiple comparisons, the only difference was between
the very severe COPD and non-COPD lung tissues (P 
0.05). Consistent with this result, c-JUN protein levels, as
assessed by using Western blot analysis, were lower in
homogenates of very severe COPD lung tissue com-
pared with the non-COPD control tissue samples (0.29-
fold, P  0.001) or the moderate COPD samples (0.26-
fold, P  0.001), but no differences were observed for
severe COPD lung tissue (Figure 1B). After adjustment
for age, sex, and cigarette pack-years, the lower c-JUN
protein levels were statistically significant in the severe
COPD (P  0.026) and very severe COPD (P  0.001)
groups. The c-JUN protein levels were significantly lower
in very severe COPD lung tissues than in non-COPD or
moderate COPD lung tissues when compared using Bon-
ferroni corrections for multiple comparisons (P  0.001).
We next evaluated c-JUN expression in the intact tissues
by IHC. Consistent with results obtained from mRNA and
protein expression data, IHC analysis of COPD and non-
COPD lung tissue sections with c-JUN antibodies revealed
decreased levels of c-JUN–positive cells in severe and very
severe COPD tissues when compared with control non-
COPD andmoderate COPD tissue sections (P 0.001, with
Bonferroni corrections for multiple comparisons; Figure 1C).
The c-JUN expression was highly detectable mainly in ep-
ithelial cells in non-COPD and moderate COPD lung tis-
sues, but its expression was gradually decreased in severe
COPD and very severe COPD tissues. These results sug-
gest that loss of c-JUN may contribute to the development
and/or progression of emphysema.
Genetic Deletion of c-Jun in the Alveolar Epithelium
To determine whether loss of c-Jun contributed to em-
physema in vivo, we deleted c-Jun in mouse lung epithe-
lium by a conditional gene-targeting approach. The mice
bearing the c-Jun floxed allele (c-Junf/f mice) were
crossed with mice bearing Cre recombinase cDNA under
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deletion in these mice, c-Junf/f and c-Junae mice were
genotyped for the presence of the Cre gene and c-Jun
floxed alleles, as outlined in Supplemental Figure S1B
(available at http://ajp.amjpathol.org). We observed both
deleted and undeleted c-Jun floxed alleles in the total
lung tissue of c-Junae mice (see Supplemental Figure S1
at http://ajp.amjpathol.org), because Cre expressed un-
der the control of the SPC promoter mainly deletes c-Jun
in type II alveolar epithelial cells and not in other lung cell
types.17 To further confirm the deletion, type II cells were
isolated from the lungs of c-Junf/f and c-Junae mice, and
genomic DNA was amplified. As anticipated, PCR ampli-
fied a high-mol. wt. deletion band (520 bp) but not the
floxed allele band (320 bp) in c-Junae cells (see Supple-
mental Figure S1C at http://ajp.amjpathol.org). These re-
sults confirmed that c-Jun was specifically deleted from
the type II epithelial cells of c-Junae mice.Genetic Disruption of c-Jun in the Alveolar
Epithelium Leads to Progressive Emphysema
To determine whether c-Jun deletion affects lung devel-
opment, c-Junae mice and Cre- negative c-Junf/f litter-
mates were sacrificed at the age of 1.5, 3, 8, or 12
months. Histological assessment of lungs from c-Junae
and c-Junf/f littermates revealed no apparent abnormalities
at the microscopic level at the age of 6 weeks (Figure 2A).
However, a histological examination of the lungs re-
vealed abnormalities, such as enlarged air spaces and
infiltration of atypical foamy alveolar macrophages, in
3-month-old c-Jun–mutant mice; this phenotype was not
detectable in their wild-type (c-Junf/f) littermates. The
presence of foamy alveolar macrophages persisted in
the lungs of c-Junae mice up to the age of 8 months. A
significant degree of alveolar space enlargement was
Figure 1. c-JUN expression in non-COPD and
COPD lung tissues. A: Real-time analysis of c-
JUN mRNA levels in non-COPD (n  21), mod-
erate COPD (n  24), severe COPD (n  13),
and very severe COPD (n  30) human lung
tissue biopsy specimens. The horizontal and ver-
tical lines were plotted as median interquartile
range. Linear regression analysis was performed
without any adjustment and with further adjust-
ment for sex, age, and cigarette pack-years. *P
0.008 for non-COPD versus very severe COPD
(one-way analysis of variance with Bonferroni
corrections was performed for multiple-group
comparisons); **P  0.05 for non-COPD versus
very severe COPD. B: Immunoblot analyses of
c-JUN in non-COPD, severe COPD, and very
severe COPD lung homogenates (left panel).
Immunoblot analysis of c-JUN in non-COPD and
moderate COPD (right panel). -Actin was
used as the reference for loading control. c-JUN
protein bands were quantified and normalized
to -actin in each sample using Bio-Rad Image
Lab software (bottom panel). The horizontal
and vertical lines were plotted as median  in-
terquartile range for each group (n  9). Linear
regression analysis was performed without any
adjustment and with further adjustment for sex,
age, and cigarette pack-years. *P  0.001 for
non-COPD versus very severe or moderate
COPD versus very severe COPD (one-way anal-
ysis of variance with Bonferroni corrections was
performed for multiple-group comparisons);
**P  0.001 for non-COPD versus very severe or
moderate COPD versus very severe COPD. C:
IHC analysis of c-JUN on lung sections of pa-
tients without COPD and patients with moder-
ate, severe, and very severe COPD. The graph
represents the number of c-JUN–positive cells.
One-way analysis of variance with Bonferroni
corrections was performed for multiple-group
comparisons. **P  0.001 for non-COPD versus
severe and very severe COPD or moderate
COPD versus severe and very severe COPD.observed in the lungs of the 8-month-old c-Junae mice,
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(see Supplemental Figure S2 at http://ajp.amjpathol.org).
However, as can be appreciated in the low-power (orig-
inal magnification, 40) images in Figure 2A, the nature
of this pathological development was heterogeneous,
with localized destruction leading to large cavities in the
parenchyma. In contrast, this striking emphysematous
phenotype was not seen in either c-Junf/f mice (Figure
2A) or wild-type mice (see Supplemental Figure S2 at
http://ajp.amjpathol.org) or wild-type mice bearing SPC-
Cre recombinase (see Supplemental Figure S3 at http://
ajp.amjpathol.org).
To determine the magnitude of the emphysema
caused by c-Jun deletion, we measured the MCL using
computer-assisted morphometric analysis (Figure 2B).
The increase in the MCL generally indicates airspace
(alveolar size) enlargement and greater severity of em-
physema.18,19 The MCL of the c-Jun–mutant mice at the
age of 1.5 months was not different from that of wild-type
mice (Figure 2B). However, the chord lengths of the
c-Junae mice were increased by 15% and 17% when
compared with c-Junf/f mice at the ages of 3 and 8
months, respectively. There was a dramatic increase inthe lung tissue damage and the MCL in c-Junae mice by
39% at the age of 12 months. The MCL of c-Junf/f murine
lungs increased by 22% at the age of 3 months when
compared with that of 1.5-month-old mice, but it re-
mained stable at this level through the age of 12 months.
To determine whether Cre recombinase expression has
any effect on the integrity of the lung structure, lungs from
wild-type mice expressing Cre recombinase under the
control of SPC promoter were harvested at the age of 12
months. There was no noticeable defect in lung structure
in these mice, as evaluated by histopathological features
and MCL quantification. The histopathological features
and MCL in these mice were comparable to those of mice
with the c-Jun floxed allele (c-Junf/f mice; see Supple-
mental Figure S3 at http://ajp.amjpathol.org). Although it
would have been best to calculate alveolar surface area,
we unfortunately did not measure the lung volumes. How-
ever, neither the simple MCL nor a calculated surface
area will reflect the extreme heterogeneity of the tissue
destruction, as seen in Figure 2A. Nevertheless, there is
clearly progressive destruction of alveolar tissue in the
c-Junae mice, suggesting a prominent role for c-Jun in the
Figure 2. Deletion of c-Jun induces inflammation and
emphysema in mice. Mice (n  8) were sacrificed at the
age of 1.5, 3, 8, or 12 months. Lungs were inflated and fixed
in 1.5% paraformaldehyde. Lung sections (5-m thick)
were prepared and stained with H&E. A: Lung images
(original magnification, 400) of 1.5-, 3-, 8-, or 12-month-
old c-Junf/f and c-Junae mice are shown. Arrows indicate
the presence of foamy macrophages. Bottom panels:
Original magnification, 40 of the lungs of c-Junae and
c-Junf/f mice at the age of 12 months. B: Serial images of
H&E-stained lung sections (original magnification, 100)
were taken and then the MCLs were measured using com-
puter-assisted morphometry with Image Pro Plus software.
The values represented are the mean  SEM. One-way
analysis of variance, followed by Newman-Keuls post hoc
analysis, was performed for multiple-group comparisons; a
two-way analysis of variance with a Bonferroni correction
was used for comparing the interaction between genotype
and age. In both cases, P 0.05 was considered statistically
significant. *P  0.05 for c-Junf/f versus c-Junae.proper maintenance of lung alveolar cell homeostasis in
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epithelial cells can promote emphysema severity with age.
Deletion of c-Jun in the Alveolar Epithelium
Causes DNA Damage in the Lung
Several studies20 have reported the presence of endo-
thelial and epithelial apoptosis in the lungs of patients
with COPD and in experimental models of COPD. To
determine whether deletion of c-Jun from alveolar type II
epithelial cells induces emphysema via cellular apoptosis
in the lungs, we performed TUNEL assays on lung sec-
tions of c-Junf/f and c-Junae mice (Figure 3). As shown in
Figure 3A, low levels of TUNEL-positive cells were pres-
ent in the lungs of c-Junae mice (approximately three
cells per field) at the age of 1.5 months, but none in
c-Junf/f mice. The number of TUNEL-positive cells grad-
ually increased in 3- and 8-month-old c-Junae mice by
7.5 and 31 cells per field, respectively (Figure 3B). This
increase in the number of TUNEL-positive cells was con-
sistent with the increase in the severity of the lung dam-
age and emphysema in c-Jun–mutant mice. In 12-month-
old c-Junae mice, the number of TUNEL-positive cells
declined to 20 per field, compared with 8-month-old lit-
termates. In contrast to the situation in c-Jun–mutant
mice, there were few apoptotic cells (one to two per field)
in the lungs of all age groups of c-Junf/f mice. These
results suggest that loss of c-Jun expression in alveolar
epithelium results in elevated levels of cellular apoptosis,
thereby leading to progressive loss of alveolar epithelium.
c-Jun Deficiency Deregulates Antioxidant
Enzyme and Inflammatory Cytokine Expression
Deregulation of antioxidant gene expression has been
implicated in lung tissue destruction, leading to emphy-
sema.5,21 Therefore, we asked whether c-Jun deficiency
would decrease antioxidant gene expression, leading to
increased levels of lung cell apoptosis. To answer this
question, we analyzed the expression levels of represen-
tative antioxidant enzymes, Gclc, Nqo1, and Hmox1. We
chose these enzymes because they play roles in cellular
detoxification and maintenance of reduction-oxidation
status and are also transcriptionally regulated by the
AP-1 transcription factor.5,21 Gene expression analysis
revealed deregulated expression of Gclc, Nqo1, and
Hmox1 in the lungs of c-Jun–mutant mice compared with
the littermate control group (Figure 4A). The mRNA ex-
pression levels of all three enzymes were significantly
lower in 3-month-old c-Jun–mutant mice than in wild-type
mice, but their expression levels between these two ge-
notypes in 8-month age groups were not statistically dif-
ferent. The expression levels of Nqo1 and Hmox1, but not
Gclc, were significantly lower in 12-month-old c-Jun–mu-
tant mice than in wild-type mice (Figure 4A). These re-
sults suggest that a lack of the c-Jun/AP-1 pathway alters
the response to cellular stress, at least in part as a result
of deregulation of antioxidant gene expression.
Several cytokines have played a role in the orchestra-
tion of inflammation in COPD by activating, recruiting,and prolonging the survival of inflammatory cells.6 We,
therefore, assessed the levels of several cytokines and
chemokines in the BAL fluid of c-Junae and c-Junf/f mice
Figure 3. c-Jun deficiency leads to DNA damage. TUNEL staining was
performed on lung tissues obtained from c-Junf/f and c-Junae mice (n  3)
using the In Situ Cell Death Detection Kit. Nuclei were stained with pro-
pidium iodide. A: Images of the TUNEL stainings of 1.5-, 3-, 8-, or 12-month-
old mice (original magnification, 200) are shown. TUNEL-positive epithe-
lial cells and macrophages are indicated with white arrows and asterisks,
respectively. B: TUNEL-positive epithelial cells were counted (10 fields per
lung section). Data are the average  SEM (n  3 mice). *P  0.05 for those
aged 1.5 months versus the other age groups; †P  0.05 for c-Junf/f versus
c-Junae mice.using multiplex cytokine assays. Of the cytokines mea-
ignifica
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CXCL1) showed a significant difference in between
c-Junae mice and their c-Junf/f littermates (Figure 4B).
BAL fluids from the 3- and 8-month age groups of
c-Junae mice had elevated levels of TNF- when com-
pared with those of their counterpart c-Junf/f littermates.
IL-12p40 levels were not different between the genotypes
at the age of 3 months, but they were markedly higher in
8-month-old c-Junae mice (83 pg/mL) than in c-Junf/f
mice (8 pg/mL). In mutant mice, although not statistically
significant, IL-12p40 levels were still higher (14 pg/mL)
than those in c-Junf/f mice (8 pg/mL) at the age of 12
months. Similarly, levels of Cxcl1 (keratinocyte derived
chemokine or human IL-8 equivalent) were significantly
elevated in c-Jun–mutant mice at the ages of 3 and 12
months, when compared with wild-type mice (Figure 4B).
Likewise, IL-13 levels were also not different between the
two genotypes in the 3- and 12-month age groups but
were significantly elevated in c-Junae mice in the
8-month age groups compared with their c-Junf/f litter-
mates (Figure 4B).
Prolonged Exposure to Cigarette Smoke
Induces Perivascular and Peribronchiolar
Inflammation in c-Jun–Mutant Mice
Because cigarette smoke is a major causative factor in
the pathogenesis of COPD and inflammation, we exam-
ined whether c-Jun deletion in alveolar epithelial cells
increases the severity of the lung pathogenesis in response
Figure 4. Expression levels of antioxidant enzymes and inflammatory cytok
and c-Junae mice, and cDNA was prepared. The expression levels of Gclc, N
was calculated using the Student’s t-test. *P  0.05 for c-Junf/f versus c-Jun
c-Junf/f and c-Junae mice. Cytokine analyses were performed with a mult
cytokines of IL-12p40, IL-13, Cxcl1 (KC), and TNF- were given (n  5). S
c-Junae mice.to cigarette smoke exposure. We exposed c-Junf/f andc-Junae (8-week-old) mice to cigarette smoke for 6
months (as detailed in Materials and Methods) and then
assessed lung inflammation and tissue damage. Lung
inflammation and air space enlargement were assessed
by inflammatory cell analysis in the BAL fluid and by
measuring the MCL of lung tissue sections, respectively.
We found elevated numbers of inflammatory cells, mainly
consisting of neutrophils, macrophages, and lympho-
cytes, in the lungs of c-Jun–mutant mice compared with
c-Junf/f mice (Figure 5A). The percentage increase in
total neutrophils in the BAL fluid of cigarette smoke–
exposed c-Junae mice over room air controls was 20-
fold greater than those in their c-Junf/f counterparts
(200% versus 10% in c-Junae versus c-Junf/f mice). Like-
wise, epithelial cell sloughing was 1.7-fold higher in
c-Junae mice compared with their c-Junf/f counterparts
(125% versus 70% in c-Junae versus c-Junf/fmice). How-
ever, the percentage increase in total cells (36% versus
37% in c-Junae versus c-Junf/f mice) and macrophages
(32% versus 36% in Junae versus c-Junf/f mice) was not
statistically different between the two genotypes after
smoke exposure. A histopathological examination re-
vealed lymphocyte infiltrates adjacent to the blood ves-
sels and airways in the lungs of c-Junaemice exposed to
cigarette smoke (Figure 5B; see also Supplemental Fig-
ure S4 at http://ajp.amjpathol.org) that resembled the
bronchus-associated lymphoid tissue phenotype ob-
served in the lung tissue of patients with COPD.22 We
then used morphometry to quantify the effects of c-Jun
deficiency on lung tissue destruction. As expected, the
Total RNA was isolated from the lungs of 1.5-, 3-, 8-, or 12-month-old c-Junf/f
Hmox1 were determined using TaqMan gene real-time probes. Significance
. B: Cytokines were measured in BAL fluids of 1.5-, 3-, 8-, or 12-month-old
spension array system using Luminex beads. The mean  SEM values of
nce was calculated using the Student’s t-test. *P  0.05 for c-Junf/f versusines. A:
qo1, and
ae mice
iplex suMCL in lungs of cigarette smoke–exposed c-Junf/f mice
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trol group (Figure 5C). However, cigarette smoke exposure
did not alter the magnitude of emphysema caused by the
deletion of c-Jun (Figure 5C). The average MCLs of ciga-
rette smoke–exposed c-Junae mice were comparable to
those of room air–exposed c-Junae mice. These results
strongly support a prominent role for c-Jun in the proper
maintenance of lung alveolar cell homeostasis and in re-
ducing the lung inflammation induced by cigarette smoke.
We further identified the cell types infiltrating the perivas-
cular and peribronchiolar regions of the lungs of c-Jun–
mutant mice by immunostaining the lung tissue sections
with the anti-CD3 and anti-B220 antibodies, which specifi-
cally stain T and B lymphocytes, respectively. Immunostain-ing revealed that the perivascular and peribronchial infil-
trates in the lungs of c-Junae mice consisted mainly of T
lymphocytes (Figure 5D) and B lymphocytes (Figure 5E).
This type of immune infiltration was not seen in the lungs of
cigarette smoke–exposed c-Junf/f mice or in the lungs of
filter air–exposed control mice of either genotype.
Discussion
Our current findings demonstrate, for the first time to our
knowledge, a critical role for the c-Jun/AP-1 pathway in
maintaining lung alveolar epithelial cell homeostasis by
Figure 5. Cigarette smoke–induced inflamma-
tion and emphysema in the lungs of c-Junf/f and
c-Junae mice. Mice were exposed to cigarette
smoke (CS) or filtered room air (RA) for 6
months. BAL fluid was collected from the right
lung, centrifuged, and stained with the Diff-Quik
stain kit. The left lung was inflated with 0.8%
agarose and fixed in 1.5% paraformaldehyde.
A: Differential cell counts were performed and
expressed as mean  SEM for total cells, neu-
trophils, macrophages, and lymphocytes. One-
way analysis of variance, followed by Newman-
Keuls post hoc analysis, was performed for
multiple-group comparisons; two-way analysis
of variance with a Bonferroni correction was
used for comparing the interaction between ge-
notype and CS. In both cases, P  0.05 was
considered statistically significant. *P  0.05 for
filtered air versus cigarette smoke; †P  0.05 for
c-Junf/f versus c-Junae mice. B: Histopatholog-
ical characteristics of lung sections showing the
perivascular and peribronchial cellular infiltrate.
Lung sections were prepared from mice exposed
to RA and CS and stained with H&E. C: Serial
images of H&E-stained lung sections (original
magnification, 100) of c-Junf/f and c-Junae
mice exposed to CS and RA were taken, and
then MCLs were measured using computer-as-
sisted morphometry with Image Pro Plus soft-
ware. The values represented are mean  SEM.
One-way analysis of variance, followed by New-
man-Keuls post hoc analysis, was performed for
multiple-group comparisons; two-way analysis
of variance with a Bonferroni correction was
used for comparing the interaction between ge-
notype and CS. In both cases, P  0.05 was
considered statistically significant.*P  0.05 for
RA versus CS exposed mice. D and E: The tissue
sections obtained from the lungs of mice ex-
posed to CS or RA were immunostained with
anti-CD3 antibodies (D) and anti-B220 antibod-
ies (E). Graphs represent the c-Jun–positive T
lymphocytes (D) and B lymphocytes (E). *P 
0.05 for filtered air vs cigarette smoke; †P 0.05,
for c-Junf/f vs c-Junae mice.reducing cellular stress and inflammation. The continual
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and persistent inflammation) in c-Junae mice is akin to
the pace of emphysema that develops in smokers. Con-
sistent with this observation, we found a substantial loss
of c-JUN expression in the lung tissues obtained from
patients with severe COPD symptoms when compared
with patients without COPD (Figure 1). More important,
the lack of the c-Jun transcription factor enhanced the
severity of cigarette smoke–induced lung inflammation
with lymphocytic infiltrates, which are observed in the
lungs of patients with COPD.22 In contrast, a specific
deletion of c-Jun in Clara cells did not cause progressive
emphysema in mice (data not shown) nor was any such
phenotype detectable in wild-type mice with Cre recom-
binase at up to the age of 12 months (see Supplemental
Figure S3 at http://ajp.amjpathol.org). Thus, it appears
that a loss of c-Jun expression specifically in the alveolar
epithelium may enhance susceptibility to the develop-
ment and progression of emphysema.
COPD is characterized by chronic bronchitis and em-
physema. Various experimental models of emphysema
have been used to elucidate the mechanisms underlying
the pathogenesis of COPD. One of these models, ciga-
rette smoke, has been widely used because it uses the
relevant causative agent that causes COPD. Research-
ers13,23 have shown that long-term exposure to cigarette
smoke in the mouse displays several of the characteristic
hallmarks of COPD, including airspace enlargement, ox-
idative stress, apoptosis, inflammation, and protease–
anti-protease imbalance. One of the limitations of the
long-term cigarette smoke model, however, is the mild
degree of emphysema it produces. Several studies have
used other nonsmoking models, such as the instillation of
elastase,24,25 vascular endothelial growth factor inhibi-
tion,26,27 caspase 3 instillation,28 and ceramide activa-
tion.29 These models have the advantage of causing
airspace enlargement in a shorter period (cigarette
smoke exposure requires 6 months), and they induce
lung inflammation and cellular apoptosis, which lead to
airspace enlargement. However, although there are lim-
itations associated with using long-term cigarette smoke
exposure in mice (eg, a lack of chronic bronchitis be-
cause of undetectable levels of mucus production), this
model has been considered the most relevant model for
COPD research because it uses the agent that causes
most COPD cases.
Both alveolar epithelial and endothelial cell apoptosis
and proliferation are deregulated in the lungs of rodents
exposed to experimental emphysema,6 as well as in the
lungs of patients with emphysema COPD.20 This pheno-
type has generally been attributed to elevated levels of
oxidative stress and protease–anti-protease imbalance
caused by the impact of cigarette smoke on lung struc-
tural cells and infiltrated leukocytes.5,30,31 Consistent with
this notion, targeted deletion of c-Jun in type II epithelial
cells gradually increased the level of apoptosis (as as-
sessed by TUNEL-positive staining) in the lungs at the
age of 1.5 to 8 months, and the number of apoptotic cells
gradually increased with age (Figure 3). This apoptotic
cell death was accompanied by an inflammatory re-
sponse at the age of 3 months, leading to a gradual lossof lung alveoli in 8- and 12-month-old mice (Figure 2A).
Although apoptosis gradually increased up to the age of
8 months in c-Junae mice, the MCL remained at the level
of 3-month-old mice. The decrease in TUNEL staining at
the age of 12 months could be attributed to the loss of
alveolar epithelium in the lung, as reflected in the histo-
pathological features and MCL (Figure 2). It is likely that
the lung epithelium switches from apoptosis to necrotic
cell death in c-Jun–mutant mice between the ages of 8
and 12 months, reflecting a change in the aging process.
Indeed, this change is consistent with the presence of
fewer apoptotic cells in these mice at the later time. From
3 to 8 months, apoptosis may be the predominant mech-
anism of cell elimination (versus necrosis) because of the
absence of c-Jun signaling. Because apoptosis generally
does not drive inflammation, a lesser MCL effect is seen
during the initial phase. This balance changes over time
to favor necrosis. Thus, the loss of c-Jun, combined with
an increase in the age of the mice, leads to an increase
in necrosis over apoptosis and the promotion of tissue
destruction and the inflammatory responses commonly
seen in emphysema. Also supporting this contention is a
previous report32 that cigarette smoke exposure induces
necrosis by inhibiting apoptosis in lung epithelial cells.
Decreased levels of CD46 complementary regulatory
protein, which regulates T-regulatory cell turnover, are
associated with a loss of lung function and the develop-
ment of emphysema in patients with COPD, and deple-
tion of CD46 in an experimental model of emphysema
has promoted the necrosis of inflammatory cells, rather
than apoptosis.33
An increased level of apoptosis was accompanied by
decreased expression of several antioxidant enzymes,
such as Gclc, Nqo1, and Hmox1, in the lungs of c-Jun–
mutant mice (Figure 4A). Previously, it was shown that
c-Jun regulates the expression of Nqo1 and Gclc by
transcriptional activation of antioxidant response ele-
ments on their promoters by associating with Nrf234 and
Hmox1 through the induction of Fos/AP-1 activity.35 Also,
mouse embryonic fibroblasts deficient in c-Jun undergo
premature senescence due to proliferation defects
caused by an increased level of spontaneous DNA dam-
age and impaired repair.36–39 Furthermore, the c-Jun/
AP-1 transcription factor is a critical regulator of cell pro-
liferation and survival. For example, the lack of c-Jun
impairs liver cell generation, mainly due to increased cell
death of hepatocytes.10 c-Jun promotes the survival of
hepatocytes by regulating the expression of inducible
nitric oxide synthase and total nitric oxide levels in exper-
imental hepatitis.40 Thus, lack of the c-Jun transcription
factor in alveolar epithelium likely results in deregulation
of the cellular reduction-oxidation state that may contrib-
ute to DNA damage, leading to the impairment of epithe-
lial cell regeneration and emphysema.
Inflammation is a common feature in the pathogenesis
of many chronic conditions, including COPD/emphy-
sema.21 Multiple cytokines orchestrate the recruitment
and activation of inflammatory cells and thereby contrib-
ute to both acute and chronic airway diseases, such as
COPD.41 In the present study, we found increased levels
of a pro-inflammatory cytokine, TNF-, in BAL fluids ob-
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pared with wild-type mice. TNF- has been implicated in
emphysema. For example, increased levels of TNF-
have been observed in patients with COPD42 and ciga-
rette smoke–induced experimental emphysema.43 c-Jun
has been shown to modulate regulated the TNF- levels
through regulating the expression of tissue inhibitor of
metalloproteinase 3,44 a potent inhibitor of TNF- con-
verting enzyme. Conditional and inducible deletion of
both c-Jun and Jun-B occurred in the epidermis of adult
mice that developed psoriasis-like inflammatory skin dis-
ease.45 An analysis of skin lesions in these double-mu-
tant mice revealed a remarkable increase in the inflam-
matory cells, consisting of T lymphocytes and
inflammatory cytokines, such as TNF-, IL-12p40, MIP-1,
and MIP-2.45 We also found increased levels of IL-13,
Cxcl1, and IL-12p40, in c-Jun–mutant mice (Figure 4B).
Lung-specific expression of IL-13 promoted the develop-
ment of emphysema and inflammation,46 whereas Cxcl1
possesses neutrophil chemoattractant activity and IL-
12p40 regulates immune responses.47 Thus, it is likely
that deregulated cytokine expression, resulting from lack
of the c-Jun/AP-1 signaling in the alveolar epithelium,
contributes to the progression of emphysema.
We noted a persistent presence of foamy (atypical)
alveolar macrophages in c-Junae mice, which was
correlated with the lung tissue damage and progres-
sion of emphysema. Consistent with this observation,
the presence of foamy (hypertrophic) alveolar macro-
phages was noted in several experimental models of
emphysema. For example, genetic disruption of SPD
causes progressive emphysema accompanied by the
hypertrophic alveolar macrophages in the lung.48,49
Gene expression analysis revealed strikingly lower lev-
els of SPA, SPC, and SPD in the lungs of c-Junae mice
when compared with their c-Junf/f counterparts (see
Supplemental Figure S5 at http://ajp.amjpathol.org).
The facts that c-Junae mice exhibited progressive em-
physema analogous to that in SPD/ mice and that
AP-1 regulates SPD expression50 strongly support our
contention that deregulation of c-Jun/AP-1–regulated
surfactant gene expression may contribute, in part, to
the progression of emphysema. In addition, both grad-
ual and age-related emphysema have been observed
in mouse models lacking -subunit of v6 integrin,51
lysosomal acid lipase,52 NADPH oxidase,30 toll-like re-
ceptor 4 and MyD88,53 and placental growth factor.54
Whether c-Jun acts as a functional effector in mediat-
ing cellular functions and maintaining the lung tissue
homeostasis regulated by these proteins remains to be
investigated in our experimental conditions. COPD is
characterized by an inflammatory response by the
lungs to inhaled substances, such as cigarette smoke
and airborne pollutants. Cigarette smoke induces both
humoral and cell-mediated immune responses via the
release and inhibition of both pro- and anti-inflamma-
tory cytokines.55 The deletion of c-Jun leads to severe
inflammation, consisting of T- and B-lymphocyte accu-
mulation around the major airways and blood vessels
in the lung (Figure 5) after cigarette smoke exposure.
To our knowledge, this is first report that c-Jun defi-ciency enhances the severity of lung inflammation with
perivascular and peribronchial lymphocyte infiltration.
Moreover, we found that c-JUN expression is de-
creased in lung tissue samples from patients with se-
vere or very severe COPD, compared with those with-
out COPD. Therefore, we propose that the loss of c-Jun
expression in alveolar epithelium may be a suscepti-
bility factor underlying cigarette smoke–induced lung
inflammation and emphysema development. Paradox-
ically, c-JUN is highly expressed in human lung cancer
tissues/cells, and its expression is correlated with a
poor prognosis in patients with lung cancer.56–59 How-
ever, transgenic overexpression of c-Jun alone in mice
does not lead to an overt phenotype in almost all tis-
sues, including the lung.60 In contrary, overexpression
of this transcription factor in hamster tracheal epithelial
cells induces their proliferation and transformation in
vitro,61 and transgenic expression of a mutant form of
c-Jun in the lung epithelial cells inhibits carcinogen-
induced lung tumorigenesis.62 The procarcinogenic ef-
fects of c-Jun in chemically and virally induced patho-
genesis are mainly attributed to its proproliferative and
anti-apoptotic effects, mediated by the up-regulation of
cell cycle genes and the suppression p53-mediated
functions, respectively.7 Although c-Jun has procarci-
nogenic effects, lack of its proproliferative and anti-
apoptotic effects may contribute to the loss of lung
tissue in c-Junae mice that are seen under our exper-
imental conditions. Whether the activation of this tran-
scription factor may prove a useful new strategy for
treating COPD or whether this approach may be prob-
lematic because it could have potential procarcino-
genic effects warrants further investigation.
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